Amvis Holdings, Inc.【JP:7071】Stock Price

Ambis Holdings is a holding company that oversees its group operations and operates the "Ishinkan" business, which focuses on management support for paid nursing homes and end-of-life care. In addition to operating paid nursing homes, the company provides hospice-style services that combine visiting nursing care, visiting care assistance, and home care support services.

The company's primary customers are elderly individuals with high medical care needs and their families. It works in partnership with hospitals and private practitioners to serve as a post-discharge placement option. Revenue is structured in three tiers: medical insurance reimbursements and long-term care insurance reimbursements from the national review and payment agency, plus non-insurance income from residents such as rent, management fees, and meal costs.

The company's business is concentrated in the single-segment Ishinkan business, which organically combines visiting services (visiting nursing care, visiting care assistance, and home care support) with facility-based services (paid nursing homes). By deploying nursing staff in adequate numbers and coordinating with external medical institutions for physician services, the company accepts patients with high medical care needs on a 24-hour basis. It has expanded operations nationwide to a capacity of approximately 6,700 residents.

The company is positioning its Ishinkan business as its core operation and has set transformation into a "full-fledged comprehensive healthcare company" within 3 to 5 years as its growth axis. The company emphasizes year-over-year increases in revenue and EBITDA, as well as EBITDA margin, as key performance indicators for growth, and has set a equity ratio target of 30% as a benchmark for financial soundness. As of September 2025, the company's equity ratio stands at 43.0%, exceeding this target. The company aims to establish Ishinkan, which it has developed to a capacity of approximately 6,700 residents, as a stable long-term revenue base.

The company differentiates itself through prioritized investment in both qualitative improvement and quantitative expansion of Ishinkan. Specifically, it has adopted a business model that deploys nursing staff extensively in hospice-type care primarily accepting end-of-life cancer patients, while complementing physician functions through external partnerships. This strength enables the company to accept residents with high medical dependency on a 24-hour basis. In parallel, the company is advancing on-site investments including education and training to reduce employee turnover, expanding staffing levels, and improving operational efficiency to enhance loyalty among both residents and employees.

For new market development and business expansion, the company plans to extend the operational expertise cultivated in eastern Japan through dominant market positioning in the Tokyo metropolitan area and establishing new bases in high-demand regions including western Japan. Additionally, through its consolidated subsidiary Ashita no Iryoku Inc., established in 2020, the company provides management support to hospitals and care facilities. As of April 2025, it began supporting six healthcare institutions, contributing to improved profitability. Going forward, the company plans to expand hands-on support to a broader range of healthcare institutions, including general hospitals and secondary care hospitals, not limited to regional areas, and aims to revitalize regional healthcare through synergies with Ishinkan.

The company's approach to technological innovation emphasizes "operational innovation" rather than mere adoption of science and equipment. It focuses on building platforms that support operational efficiency and admission-discharge coordination, standardizing back-office functions, improving operations through data utilization, and leveraging digital tools to support talent development. Through these initiatives, the company aims to strengthen EBITDA and cash flow generation, manage indicators such as Net Debt/EBITDA, and pursue sustainable growth.